Jean‐Marc Nabholtz

5.4k total citations · 1 hit paper
54 papers, 3.2k citations indexed

About

Jean‐Marc Nabholtz is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Jean‐Marc Nabholtz has authored 54 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 29 papers in Cancer Research and 17 papers in Genetics. Recurrent topics in Jean‐Marc Nabholtz's work include Cancer Treatment and Pharmacology (26 papers), Breast Cancer Treatment Studies (26 papers) and HER2/EGFR in Cancer Research (25 papers). Jean‐Marc Nabholtz is often cited by papers focused on Cancer Treatment and Pharmacology (26 papers), Breast Cancer Treatment Studies (26 papers) and HER2/EGFR in Cancer Research (25 papers). Jean‐Marc Nabholtz collaborates with scholars based in France, United States and Canada. Jean‐Marc Nabholtz's co-authors include Aman U. Buzdar, J.F.R. Robertson, Mark L. Steinberg, Mia von Euler, Michaël Pollak, John R. Mackey, A Mangalik, Alan Webster, William N. Harwin and G. Burton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jean‐Marc Nabholtz

52 papers receiving 3.1k citations

Hit Papers

Anastrozole Is Superior to Tamoxifen as First-Line Therap... 2000 2026 2008 2017 2000 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
    2000 738 citations Jean‐Marc Nabholtz, Aman U. Buzdar et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Marc Nabholtz France 24 1.9k 1.3k 1.2k 772 508 54 3.2k
M. Bontenbal Netherlands 31 2.1k 1.1× 1.2k 0.9× 667 0.6× 480 0.6× 575 1.1× 66 3.4k
J Cuzick United Kingdom 7 2.0k 1.1× 2.0k 1.5× 1.6k 1.4× 561 0.7× 565 1.1× 10 3.6k
José Bines Brazil 22 2.7k 1.5× 1.4k 1.0× 694 0.6× 1.0k 1.3× 549 1.1× 94 3.7k
John F. R. Robertson United Kingdom 25 1.3k 0.7× 803 0.6× 807 0.7× 564 0.7× 882 1.7× 52 2.7k
D. Amoroso Italy 23 2.0k 1.1× 925 0.7× 668 0.6× 791 1.0× 455 0.9× 104 2.8k
Giorgio Massimini Italy 16 1.3k 0.7× 705 0.5× 884 0.8× 861 1.1× 899 1.8× 33 2.8k
M. Namer France 29 2.4k 1.3× 1.4k 1.0× 612 0.5× 982 1.3× 562 1.1× 122 3.7k
I E Smith United Kingdom 23 1.8k 1.0× 1.5k 1.2× 1.1k 1.0× 657 0.9× 777 1.5× 59 3.5k
Tiffany A. Traina United States 30 2.4k 1.3× 1.6k 1.2× 698 0.6× 1.4k 1.8× 1.1k 2.1× 146 4.0k
A. Rubagotti Italy 32 1.6k 0.9× 1.2k 0.9× 1.3k 1.1× 934 1.2× 638 1.3× 131 3.7k

Countries citing papers authored by Jean‐Marc Nabholtz

Since Specialization
Citations

This map shows the geographic impact of Jean‐Marc Nabholtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Marc Nabholtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Marc Nabholtz more than expected).

Fields of papers citing papers by Jean‐Marc Nabholtz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Marc Nabholtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Marc Nabholtz. The network helps show where Jean‐Marc Nabholtz may publish in the future.

Co-authorship network of co-authors of Jean‐Marc Nabholtz

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Marc Nabholtz. A scholar is included among the top collaborators of Jean‐Marc Nabholtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Marc Nabholtz. Jean‐Marc Nabholtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alsaleh, Khalid, Arwa Ali, Jawaher Ansari, et al.. (2017). Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncology Letters. 14(1). 337–344. 30 indexed citations
2.
Chalabi, Nasséra, Catherine Abrial, Nina Radosevic‐Robin, et al.. (2015). Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology. 95(1). 88–104. 68 indexed citations
3.
Planchat, E., Catherine Abrial, Émilie Thivat, et al.. (2011). Late lines of treatment benefit survival in metastatic breast cancer in current practice?. The Breast. 20(6). 574–578. 19 indexed citations
4.
Nabholtz, Jean‐Marc, Marie‐Ange Mouret‐Reynier, Xavier Durando, et al.. (2009). Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opinion on Pharmacotherapy. 10(9). 1435–1447. 23 indexed citations
5.
Burzykowski, Tomasz, Marc Buyse, Martine Piccart, et al.. (2008). Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1987–1992. 268 indexed citations
6.
Piccart, Martine, Tomasz Burzykowski, Marc Buyse, et al.. (2008). Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1980–1986. 164 indexed citations
7.
Nabholtz, Jean‐Marc & Joseph Gligorov. (2005). Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opinion on Pharmacotherapy. 6(9). 1555–1564. 12 indexed citations
8.
Nabholtz, Jean‐Marc. (2003). Advanced breast cancer updates on anastrozole versus tamoxifen. The Journal of Steroid Biochemistry and Molecular Biology. 86(3-5). 321–325. 17 indexed citations
9.
Lohrisch, Caroline, et al.. (2003). Node positive breast cancer. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 107–146. 18 indexed citations
10.
Nabholtz, Jean‐Marc, et al.. (2003). Advances in the Use of Taxanes in the Adjuvant Therapy of Breast Cancer. Clinical Breast Cancer. 4(3). 187–192. 22 indexed citations
11.
Nabholtz, Jean‐Marc, et al.. (2003). Advances in the Use of Taxanes in the Adjuvant Therapy of Breast Cancer. Clinical Breast Cancer. 4(3). 187–192. 10 indexed citations
12.
Thürlimann, Beat, J.F.R. Robertson, Jean‐Marc Nabholtz, Aman U. Buzdar, & Jacques Bonneterre. (2003). Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European Journal of Cancer. 39(16). 2310–2317. 57 indexed citations
13.
Nabholtz, Jean‐Marc, David Reese, Mark A. Lindsay, & A. Riva. (2002). HER2-Positive Breast Cancer: Update on Breast Cancer International Research Group Trials. Clinical Breast Cancer. 3. S75–S79. 35 indexed citations
14.
Nabholtz, Jean‐Marc, et al.. (2002). Evidence for the use of chemotherapy in breast cancer. International Journal of Clinical Oncology. 7(4). 254–264. 9 indexed citations
15.
Buzdar, Aman U., J.F.R. Robertson, W. Eiermann, & Jean‐Marc Nabholtz. (2002). An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 95(9). 2006–2016. 213 indexed citations
16.
Thürlimann, Beat, J.F.R. Robertson, J. Bonneterre, A. U. Buzdar, & Jean‐Marc Nabholtz. (2001). Efficacy of tamoxifen (TAM) following Anastrozole (AN) as first-line treatment for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Patients (PTS). European Journal of Cancer. 37. 5–5. 6 indexed citations
17.
Nabholtz, Jean‐Marc, et al.. (2000). Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?. Expert Opinion on Pharmacotherapy. 1(2). 187–206. 54 indexed citations
18.
Cumming, Ceinwen E., Alan Lees, Jean‐Marc Nabholtz, et al.. (1997). Sexuality, Body Image and Quality of Life after High Dose or Conventional Chemotherapy for Metastatic Breast Cancer. The Canadian Journal of Human Sexuality. 6(1). 1. 23 indexed citations
19.
Matsuzaki, Akinobu, Jean‐Marc Nabholtz, Susan Nahirniak, & Anna Janowska‐Wieczorek. (1997). Endogenous Erythropoietin, Tumor Necrosis Factor-α and Interleukin-6 Levels after Peripheral Blood Stem Cell Transplantation. Hematology. 2(2). 151–159. 4 indexed citations
20.
Al‐Tweigeri, Taher, Jean‐Marc Nabholtz, & John R. Mackey. (1996). Ocular toxicity and cancer chemotherapy: A review. Cancer. 78(7). 1359–1373. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Bontenbal Breakdown of academic impact, for papers by J Cuzick Breakdown of academic impact, for papers by José Bines Breakdown of academic impact, for papers by John F. R. Robertson Breakdown of academic impact, for papers by D. Amoroso Breakdown of academic impact, for papers by Giorgio Massimini Breakdown of academic impact, for papers by M. Namer Breakdown of academic impact, for papers by I E Smith Breakdown of academic impact, for papers by Tiffany A. Traina Breakdown of academic impact, for papers by A. Rubagotti
Rankless by CCL
2026